Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Ranee Mehra(University of Maryland, Baltimore), Robert L. Ferris(University of Pittsburgh), Yael Flamand(Dana-Farber Cancer Institute), Harry Quon(Johns Hopkins University), Wayne M. Koch(Johns Hopkins University), Nabil F. Saba(Emory University), Joaquín J. García(Mayo Clinic), R. Bryan Bell(Takara (United States)), Umamaheswar Duvvuri(City University of New York), Giovana R. Thomas(National Institutes of Health), Bert W. O’Malley(Baylor College of Medicine), Neil D. Gross(The University of Texas MD Anderson Cancer Center), Miriam N. Lango(Fox Chase Cancer Center), Gregory S. Weinstein(University of Pennsylvania), Rodrigo Bayon(University of Iowa), Enver Özer(The Ohio State University Wexner Medical Center), Barbara Burtness(Yale University)
Cited by 12
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
|Endocrine Reviews|2004|924